Skip to main content
. 2021 Jul 21;14:3443–3463. doi: 10.2147/JIR.S315938

Figure 4.

Figure 4

Immunostaining of MyD88. Photomicrographs of specimens from: (N), (NSC), and (CRID3) show scanty MyD88 expression; (DSS), shows marked expression of MyD88 in the damaged crypts and inflammatory cells (filled arrow), such as polymorphonuclear leukocytes and monocytes; (DSS/NSC), shows moderate decrease in the MyD88 expression (filled arrow); (DSS/CRID3), shows increased expression of MyD88 (filled arrow); (DSS/NSC/CRID3), displays significant decrease in the MyD88 expression in the epithelia of glands and crypts (filled arrow). As shown in MyD88 immunoreactivity evaluation figure, a significant decrease in the percentage of MyD88 immunopositive cells/1000 counted cells was detected in rats treated with DSS/NSC and DSS/NSC/CRID3 compared with the untreated DSS rats. The insignificant change in the percentage of MyD88 immunopositive cells/1000 counted cells was observed in rats treated with CRID3. MyD88 IHC, bar = 50 µm. ++++P < 0.0001 vs N, +++P < 0.001 vs N, ****P < 0.0001 vs DSS, ###P < 0.001 vs DSS/CRID3, $P < 0.05 DSS/CRID3 vs DSS/NSC.